Skip to main content

Table 1 Characteristics of the study population

From: Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

  Overall population N = 158 Patients with KTD n = 42 Patients without KTDn = 116 p*
Female (%) 34 21.5% 8 19.0% 26 22.4% 0.649
Age [yrs] median (IQR) 42 35–48 42 37–45 42 34–49 0.591
Non-Caucasian (%) 5 3.2% 2 4.8% 3 2.6% 0.490
BMI (Kg/m2) median (IQR) 22,9 20,3–25,2 23,5 20,7–25,4 22,5 20,2–25,2 0.339
TDF as part of first ARV regimen (%) 83 52,5% 14 33,3% 69 59,5% 0.004
Previous therapy duration [yrs] median (IQR) 0.0 0.0–6.1 0.6 0.0–8.2 0.0 0.0–3.8 0.034
TDF duration (months) median (IQR) 66 24–101 76 30–110 59 23–95 0.090
Use of protease inhibitors (%) 103 65.2% 26 61.9% 77 66.4% 0.602
CD4+ (cells/μL) median (IQR) 373 228–599 430 251–635 371 224–580 0.638
HIV-RNA (log cps/mL) median (IQR) 3.8 0.0–5.0 0.0 0.0–4.5 4.0 0.0–5.0 0.012
Creatinine (mg/dL) median (IQR) 0.84 0.72–0.94 0.84 0.70–0.99 0.83 0.73–0.92 0.534
GFR (MDRD equation) median (IQR) 103 89–117 106 89–118 101 89–117 0.586
HCV coinfection (%) 18 11.4% 6 14.3% 12 10.3% 0.491
Diabetes (%) 11 7.0% 5 11.9% 6 5.2% 0.142
Hypertension (%) 20 12.7% 8 19.0% 12 10.3% 0.146
Bone diseasea (%) 55 34.8% 23 54.8% 32 27.6% 0.002
  1. Abbreviations: yrs. years, IQR Inter quartile range, cps copies, BMI body mass index, GFR glomerular filtration rate, MDRD The Modification of Diet in Renal Disease, TDF tenofovir diproxil fumarate, ARV antiretroviral therapy; aosteopenia/osteoporosis; *p values are for χ2 or Fisher’s exact test and Mann-Whitney test